HOME ·

RIBOLIFE-B

RIBOLIFE-B (06938.HK): Issues 14,087,085 Consideration Shares to Buy Remaining 49.71% of Ribocure
Tags：
NewTimeSpaceRIBOLIFE-B06938.HK
2026-10-19
RIBOLIFE-B (06938.HK): files EU Phase I trial for obesity drug RBD3133
Tags：
RIBOLIFE-B06938.HKEU
2026-10-08
RIBOLIFE-B (06938.HK): Included in Hang Seng Composite Index constituents and Stock Connect list effective 7 September
Tags：
RIBOLIFE-B06938.HKStock Connect
2026-09-07
RIBOLIFE-B (06938.HK): Positive Phase IIa Results for Core Asset Vortosiran in CAD; Maximum FXI Activity Reduction Reaches 92%
Tags：
RIBOLIFE-B06938.HKClinical Data
2026-07-22